Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

Fig. 3Fig. 3Fig. 3Fig. 3Fig. 3

Pooled hazard ratios for A hospitalization for heart failure, B all-cause death, C composite of hospitalization for heart failure or all-cause death, D myocardial infarction, and E stroke stratified by subgroups (Intent-to-treat analysis; adjusted). Event rate, events per 100-person years; ACE angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, oGLD other glucose-lowering drug, SGLT-2i sodium–glucose cotransporter-2 inhibitor

Back to article page